Zafgen Inc. (NASDAQ:ZFGN) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $3.06 and last traded at $3.07, with a volume of 2,113,409 shares trading hands. The stock had previously closed at $3.24.

Several research analysts have recently commented on the stock. Leerink Swann reissued a “market perform” rating and issued a $6.00 price objective on shares of Zafgen in a research note on Wednesday. Royal Bank Of Canada reiterated an “outperform” rating and issued a $19.00 price target on shares of Zafgen in a research note on Tuesday, April 5th. FBR & Co reiterated a “buy” rating and issued a $20.00 price target on shares of Zafgen in a research note on Monday, April 4th. Cowen and Company downgraded shares of Zafgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Finally, Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research note on Thursday, May 12th. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $10.06.

The company’s market cap is $81.54 million. The firm has a 50 day moving average price of $6.32 and a 200-day moving average price of $6.56.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.09. During the same quarter last year, the company posted ($0.53) EPS. Equities analysts expect that Zafgen Inc. will post ($2.64) EPS for the current year.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.